NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The global liver cancer drugs market size is estimated to increase by USD 5.29 billion from 2021 to 2026. The market's growth momentum will accelerate at a CAGR of 14.67%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Discover some insights on the market size before buying the full report -Request a sample report

Liver cancer drugs market - Customer Landscape
To help companies evaluate and develop growth strategies, the report outlines –

• Key purchase criteria
• Adoption rates
• Adoption lifecycle
• Drivers of price sensitivity

Liver cancer drugs market – Vendor analysis
Vendor offerings -

• AstraZeneca Plc - The company offers Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
• Bayer AG - The company offers drugs, treatment, and diagnosis for liver cancer.
• Bristol-Myers Squibb Co. - The company offers drugs and treatment for patients having cancer.
• Eisai Co. Ltd. - The company offers LENVIMA, which is a systemic therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC).
• For details on vendors and their offerings – Buy the report!

Vendor landscape –

The global liver cancer drugs market is fragmented, with the presence of several vendors. A few prominent vendors that offer liver cancer drugs in the market are Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Q BioMed Inc. and others.

The vendors are deploying growth strategies such as acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share. Large vendors are acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share. Vendors are also focusing on improving their profitability. These factors are expected to further intensify the completion in the market during the forecast period.

Liver cancer drugs market - Segmentation assessment

Segment overview
Technavio has segmented the market based on type (immunotherapy and targeted therapy).

• The immunotherapy segment will account for a significant share of the market growth during the forecast period. Immunotherapy is a specific type of treatment that uses the immune system of the body to fight cancer. Currently, the market has three immunotherapies for liver cancer, namely KEYTRUDA, TECENTRIQ, and OPDIVO. Therefore, the growing use of immunotherapy will drive the growth of this segment during the forecast period.  

Geography overview
Based on geography, the global liver cancer drugs market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global liver cancer drugs market.

• North America will account for 42% of the market's growth during the forecast period. The US and Canada are the key countries for the liver cancer drugs market in the region. However, market growth in North America will be slower than the growth of the market in Europe and Asia. The development and launch of treatment therapies for liver cancer will drive the liver cancer drugs market growth in the region during the forecast period.

Download a sample report

Liver cancer drugs market – Market dynamics

Leading drivers - The increasing incidence of liver cancer is driving the growth of the market. The risk of liver cancer depends on the etiology. Hepatitis B and C and underlying cirrhosis are the main risk factors. In the US, hepatitis C is present in more than half of the patients with certain liver cancers. Fatty liver is a major cause of liver cancer in the US, followed by hepatitis C. Long-term alcohol consumption can also increase the incidence of liver cancer. Moreover, diabetes, obesity, and related non-alcoholic fatty liver disease can also be associated with an increase in the incidence of liver cancer. These factors will drive the market growth during the forecast period.

Key trends - The use of mABs is a key trend in the market. The use of monoclonal antibody (mAB) therapies is a new approach to treating liver cancer. Research is also being conducted to develop high-stability and high-affinity antibodies and fragments, which can target tumor-specific antigens in liver cancer. Monoclonal antibodies are sensitive and can create a level of specificity that reduces the chances of side effects. In addition, they are highly stable. These factors will support market growth during the forecast period.

Major challenges - Surgical resection and transplantation being the only curative option will challenge the liver cancer drugs market during the forecast period. The treatment of liver cancer is based on the stage of the disease and the functioning of the organ. However, disease-modifying drugs are unavailable, which makes surgical treatment the only recommended option. However, surgery is often associated with a high recurrence rate of tumors. These factors will hinder the growth of the market during the forecast period.

Drivers, trends, and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report!

What are the key data covered in this liver cancer drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the liver cancer drugs market between 2022 and 2026
• Precise estimation of the size of the liver cancer drugs market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the liver cancer drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of liver cancer drugs market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The breast cancer therapeutics market size is expected to increase by USD 13.85 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.95%. This report extensively covers segmentation by product (targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

The colorectal cancer therapeutics market size is expected to increase by USD 2.45 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.43%. This report extensively covers segmentation by type (targeted therapy, immunotherapy, and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Browse for Technavio's health care market reports

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type 
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Immunotherapy - Market size and forecast 2021-2026
• Exhibit 28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)

• 5.4 Targeted therapy - Market size and forecast 2021-2026
• Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AstraZeneca Plc 
• Exhibit 85: AstraZeneca Plc - Overview
• Exhibit 86: AstraZeneca Plc - Product / Service
• Exhibit 87: AstraZeneca Plc - Key news
• Exhibit 88: AstraZeneca Plc - Key offerings

• 10.4 Bayer AG 
• Exhibit 89: Bayer AG - Overview
• Exhibit 90: Bayer AG - Business segments
• Exhibit 91: Bayer AG - Key news
• Exhibit 92: Bayer AG - Key offerings
• Exhibit 93: Bayer AG - Segment focus

• 10.5 Bristol-Myers Squibb Co. 
• Exhibit 94: Bristol-Myers Squibb Co. - Overview
• Exhibit 95: Bristol-Myers Squibb Co. - Product / Service
• Exhibit 96: Bristol-Myers Squibb Co. - Key offerings

• 10.6 Eisai Co. Ltd. 
• Exhibit 97: Eisai Co. Ltd. - Overview
• Exhibit 98: Eisai Co. Ltd. - Business segments
• Exhibit 99: Eisai Co. Ltd. - Key offerings
• Exhibit 100: Eisai Co. Ltd. - Segment focus

• 10.7 Eli Lilly and Co. 
• Exhibit 101: Eli Lilly and Co. - Overview
• Exhibit 102: Eli Lilly and Co. - Business segments
• Exhibit 103: Eli Lilly and Co. - Key offerings
• Exhibit 104: Eli Lilly and Co. - Segment focus

• 10.8 Eureka Therapeutics 
• Exhibit 105: Eureka Therapeutics - Overview
• Exhibit 106: Eureka Therapeutics - Product / Service
• Exhibit 107: Eureka Therapeutics - Key offerings

• 10.9 Gilead Sciences Inc. 
• Exhibit 108: Gilead Sciences Inc. - Overview
• Exhibit 109: Gilead Sciences Inc. - Business segments
• Exhibit 110: Gilead Sciences Inc. - Key news
• Exhibit 111: Gilead Sciences Inc. - Key offerings
• Exhibit 112: Gilead Sciences Inc. - Segment focus

• 10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
• Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
• Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings

• 10.11 Lion TCR Pte. Ltd 
• Exhibit 116: Lion TCR Pte. Ltd - Overview
• Exhibit 117: Lion TCR Pte. Ltd - Product / Service
• Exhibit 118: Lion TCR Pte. Ltd - Key offerings

• 10.12 Merck and Co. Inc. 
• Exhibit 119: Merck and Co. Inc. - Overview
• Exhibit 120: Merck and Co. Inc. - Business segments
• Exhibit 121: Merck and Co. Inc. - Key news
• Exhibit 122: Merck and Co. Inc. - Key offerings
• Exhibit 123: Merck and Co. Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations 
• Exhibit 130: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Newsroom: https://newsroom.technavio.org/news/liver-cancer-drugsmarket

View original content to download multimedia:https://www.prnewswire.com/news-releases/liver-cancer-drugs-market-size-to-grow-by-usd-5-29-billion-from-2021-to-2026-a-descriptive-analysis-of-customer-landscape-vendor-assessment-and-market-dynamics---technavio-301740373.html

SOURCE Technavio